Mark Lubberink

Rapid Decrease in Delivery of Chemotherapy to Tumors after Anti-VEGF Therapy: Implications for Scheduling of Anti-Angiogenic Drugs

Astrid A.M. van der Veldt, Mark Lubberink, Idris Bahce et al. · Cancer Cell · 2012 · 336 citations · Full text

Medicine, Oncology, Pharmacology +17

Blood–brain barrier P-glycoprotein function in Alzheimer's disease

Daniëlle M. E. van Assema, Mark Lubberink, Martin Bauer et al. · Brain · 2011 · 315 citations · Full text

Medicine, Neurology, Neuroscience +17

Altered Myocardial Substrate Metabolism and Decreased Diastolic Function in Nonischemic Human Diabetic Cardiomyopathy

Luuk J. Rijzewijk, R.W. van der Meer, Hildo J. Lamb et al. · Journal of the American College of Cardiology · 2009 · 308 citations · Full text

Medicine, Cardiology, Physiology +16

Individualized Dosimetry of Kidney and Bone Marrow in Patients Undergoing ¹⁷⁷Lu-DOTA-Octreotate Treatment

Mattias Sandström, Ulrike Garske‐Román, Silvia Johansson et al. · Journal of Nuclear Medicine · 2012 · 287 citations · Full text

Medicine, Nuclear Medicine, Radiology +17

Measuring HER2-Receptor Expression In Metastatic Breast Cancer Using [⁶⁸Ga]ABY-025 Affibody PET/CT

Jens Nørkær Sørensen, Irina Velikyan, Dan Sandberg et al. · Theranostics · 2015 · 268 citations · Full text

Medicine, Nuclear Medicine, Oncology +17